Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO | Synapse
March 3, 2026
Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO
Key Points
Bone mineral density changes signify important health implications for patients with cystic fibrosis, especially with long-term treatment.
After starting elexacaftor-tezacaftor-ivacaftor, patients showed notable changes in bone mineral density across youth and adults.
Observational analysis reveals these changes, indicating a potential benefit from the intervention on bone health.
Further evaluation is needed to understand the long-term impact of this intervention on overall bone health.